IMRX
Immuneering Corp
NASDAQ: IMRX · HEALTHCARE · BIOTECHNOLOGY
$5.34
-0.84% today
Updated 2026-05-05
Market cap
$345.48M
P/E ratio
—
P/S ratio
563.62x
EPS (TTM)
$-1.27
Dividend yield
—
52W range
$1 – $10
Volume
0.9M
Immuneering Corp (IMRX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.92M | $2.31M | $2.08M | $316952.00 | $455.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | +20.4% | -10.0% | -84.8% | -99.9% | -100.0% | — |
| Cost of revenue | $1.22M | $1.28M | $1.15M | $158122.00 | $764138.00 | $713451.00 | $698887.00 |
| Gross profit | $696739.00 | $1.03M | $926888.00 | $158830.00 | $-764138.00 | $-713451.00 | $-698887.00 |
| Gross margin | 36.3% | 44.6% | 44.6% | 50.1% | -167942.4% | — | — |
| R&D | $4.28M | $15.00M | $26.54M | $36.27M | $41.62M | $47.96M | $42.05M |
| SG&A | $2.71M | $3.11M | $8.27M | $15.61M | $16.76M | $16.08M | $17.30M |
| Operating income | $-6.29M | $-17.08M | $-33.89M | $-51.74M | $-58.41M | $-64.07M | $-59.38M |
| Operating margin | -327.7% | -739.0% | -1629.2% | -16325.8% | -12837997.1% | — | — |
| EBITDA | $-7.34M | $-17.00M | $-33.73M | $-51.47M | $-58.06M | $-63.69M | $-58.68M |
| EBITDA margin | -382.4% | -735.6% | -1621.5% | -16238.4% | -12760703.7% | — | — |
| EBIT | $-7.36M | $-17.08M | $-33.89M | $-51.75M | $-58.41M | $-64.07M | $-59.38M |
| Interest expense | $351302.00 | $42656.00 | $201908.00 | $1.01M | — | — | — |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-7.71M | $-17.04M | $-33.54M | $-50.51M | $-53.47M | $-61.04M | $-56.02M |
| Net income growth (YoY) | — | -121.0% | -96.8% | -50.6% | -5.9% | -14.1% | +8.2% |
| Profit margin | -401.6% | -737.2% | -1612.3% | -15937.3% | -11752004.8% | — | — |